A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. - Wikidata - awgldk - TriplyDB

A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.

A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.

http://www.wikidata.org/entity/Q37162734

about

Fibroblast growth factor 23 Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?Magnesium in CKD: more than a calcification inhibitor?A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats.Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study.Magnesium: a renewed player of vascular ageing in diabetic CKD patients?Serum Magnesium and Sudden Death in European Hemodialysis Patients CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.Next-generation phosphate binders: focus on iron-based binders.Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.The challenge of controlling phosphorus in chronic kidney disease.Magnesium and cardiovascular complications of chronic kidney disease.Contemporary management of phosphorus retention in chronic kidney disease: a review.Advances in pharmacotherapy for secondary hyperparathyroidism.Phosphate Binders and Clinical Outcomes in Patients with Stage 5D Chronic Kidney Disease.Clinical features of CKD-MBD in Japan: cohort studies and registry.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Role of vascular calcification inhibitors in preventing vascular dysfunction and mortality in hemodialysis patients.Clinical aspects of magnesium physiology in patients on dialysis.Dietary factors and fibroblast growth factor-23 levels in young adults with African ancestry.Magnesium supplementation: A consideration in dialysis patients.Optimal phosphate control: still an unmet need in chronic kidney disease patients Treatment of hyperphosphatemia based on specific interactions between phosphorus and Zr(iv) active centers of nano-MOFs

P2860

Q26829294-9CB55971-6C33-45C1-9E50-F8E7C8748F1F Q27002431-EC09EF9A-6469-4C0D-B468-F0582476071D Q27027086-A35ED947-985F-4454-B92F-9067089D7B87 Q34205168-A1F1DD28-FF7B-4C83-8CFD-DCB45AC99DF0 Q34784711-39AAF8AB-DBF7-45CA-837B-C94C68F7393C Q35227651-65471B7F-1AC5-46F9-9E97-533F458988F3 Q35850564-52B1BE92-858D-44B4-9F76-35DEEB830120 Q37279085-A69ED010-9A6C-42E1-8008-8478A40470EB Q38200883-1A87EE1B-6EAE-47FE-ACD5-600C53A4373A Q38202179-E68ECF23-7D2D-4C6A-8F0B-8033A8E349DD Q38210438-937FA075-B42F-4B79-A655-1E415E3BCAE7 Q38213502-E8767E7F-3AB9-41E0-A2EB-3DA5AB0A8F84 Q38253227-EDE8BF88-4EDC-4850-91D8-A43318DFA71D Q38377286-501E9EF1-4D73-4790-9CC2-66F3760704BE Q38473932-392BB862-9494-43F6-A644-1D307A932E6D Q38511621-FE9BDFE4-6BCF-4CBE-B280-6BA03ABC6557 Q38544533-A46FD4CD-3B35-496B-BE98-964053DE5313 Q38567745-7A0F9C94-CC03-49F6-8DA1-E091F23A7EBC Q38784139-AD2382DA-2198-42A1-B1A9-14F2396E539C Q38828902-6A615416-CFD5-4F01-814A-E7E314211347 Q39369106-EB099882-FB97-4260-A489-898807EE94D0 Q39369171-546AE65B-5D93-4352-9AA8-64345847106A Q40429347-925E2B6D-2474-42AA-B6C7-C4B5A6862C05 Q50074589-4AC8B971-18DF-4059-8059-DD7DB32A1484 Q57217288-2812D436-4068-48EE-B355-00710FD4F096 Q57470029-C977F22C-1CB0-40D9-9DC7-009040B7283B

P2860

A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.

http://www.wikidata.org/entity/Q37162734

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A comparison of calcium acetat ...... controlled, randomized study.

@en

A comparison of calcium acetat ...... controlled, randomized study.

@nl

type

label

A comparison of calcium acetat ...... controlled, randomized study.

@en

A comparison of calcium acetat ...... controlled, randomized study.

@nl

prefLabel

A comparison of calcium acetat ...... controlled, randomized study.

@en

A comparison of calcium acetat ...... controlled, randomized study.

@nl

P1433

Q37162734-3CED11A8-4D11-4937-B9EF-F367A66AB360

P1476

Q37162734-3ED8FA8C-52E3-4D2D-9A72-BC163F547F2D

P2093

Q37162734-20EB1351-A2FA-419C-B6E4-9C6896FC9BBE

Q37162734-3903700B-CCAC-4525-B96D-D2D85D0B51C2

Q37162734-5A07C239-5CF4-490A-9169-EFA27F8A6E4F

Q37162734-9184E019-930C-4CD6-9122-677465F22B71

Q37162734-CEF0B1D2-F5BD-4396-8BC3-07E27DBD41A9

Q37162734-D92950BC-EC43-4CDC-9797-665E59CA676B

Q37162734-F2690550-2FC5-42C8-8895-784AE585C389

P2860

Q37162734-04E98A9B-2EAE-4A4B-A9D0-8FA0AD14147C

Q37162734-0ADA8601-A6E9-4F50-AB7E-3A15F327303A

Q37162734-158FB4E5-C1D7-4262-A90D-47E621677B44

Q37162734-19E9A6D5-2BBF-4487-9792-F0568D4970CC

Q37162734-235CEFA1-1B93-49EC-86AD-A0F9F6CDFC50

Q37162734-23CEC8AF-F059-4206-BB61-E536482929AE

Q37162734-31384722-A92D-4BFD-B0FC-63A54A3E3C73

Q37162734-3723E7B7-C242-464C-9360-F1AEC3E1C0A5

Q37162734-41569858-6A28-4DEE-ACC2-1A6DF02D9315

Q37162734-48745DD1-06BB-4CE9-8CF6-ECF6DD6192A8

P304

Q37162734-C61EFD5C-C299-4740-8EDC-58FDF59939B0

P31

Q37162734-E6FE3D56-C0C7-4E0B-98C6-8D360DF52C74

P356

Q37162734-13C58509-1383-49FC-B21B-2CFA1D13553E

P407

Q37162734-740E97B5-8776-428F-BAE0-EABD457B8B0E

P433

Q37162734-ECFC7426-536A-4364-A15C-0BE1C5C143EC

P478

Q37162734-E574C97F-1264-4D4C-B1F0-F348706D8CAA

P50

Q37162734-4BA6D39E-00B7-4DB5-A7EA-BC23307E65B0

P577

Q37162734-C5FB3765-E36D-4BF3-9128-52FFC1F1D08C

P5875

Q37162734-2888D114-98E3-4EA7-8A89-CF69A0295C48

P698

Q37162734-45B914AE-96AE-4580-A83C-C5C2E09C6B11

P921

Q37162734-a9606753-5229-4f0f-bc0e-4cab424f86b9

P932

Q37162734-9E943887-3D03-4D04-893C-42E37F5DDC93

P356

P1433

Nephrology Dialysis Transplantation

P1476

A comparison of calcium acetat ...... controlled, randomized study.

@en

P2093

Adrian Ghenu

http://www.w3.org/2001/XMLSchema#string

Angel L M de Francisco

http://www.w3.org/2001/XMLSchema#string

Barbara Marzell

http://www.w3.org/2001/XMLSchema#string

Beatrix Büschges-Seraphin

http://www.w3.org/2001/XMLSchema#string

Jutta Passlick-Deetjen

http://www.w3.org/2001/XMLSchema#string

Miroslaw Kroczak

http://www.w3.org/2001/XMLSchema#string

Pedro Ponce

http://www.w3.org/2001/XMLSchema#string

P2860

Hypomagnesaemia, the kidney and the vessels

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability

Acute metabolic acidosis enhances circulating parathyroid hormone, which contributes to the renal response against acidosis in the rat.

Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD.

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.

Calcium deficiency reduces circulating levels of FGF23.

P304

2383-2392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFT203

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

240308972

http://www.w3.org/2001/XMLSchema#string

P698

23787550

http://www.w3.org/2001/XMLSchema#string

P921

Béésh Łikoní

P932

3769980

http://www.w3.org/2001/XMLSchema#string